Molecular Basis of Cell Growth Control by the TOR Kinase
TOR 激酶控制细胞生长的分子基础
基本信息
- 批准号:6437233
- 负责人:
- 金额:$ 34.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-01 至 2006-11-30
- 项目状态:已结题
- 来源:
- 关键词:Caenorhabditis elegans alternatives to animals in research biological signal transduction cell adhesion cell growth regulation enzyme activity enzyme induction /repression genetically modified animals mutant pharmacology phosphoprotein phosphatase phosphoproteins phosphorylation protein kinase sirolimus suppressor mutations
项目摘要
DESCRIPTION (provided by applicant): TOR was discovered as the largest of Rapamycin; the latter is a potent and clinically important immunosuppressive
and potential antiproliferative drug. All of rapamycins pharmacologic actions
appear to he due to its ability to inhibit TOR function. TOR is a giant protein
kinase in the PIK family, whose catalytic domain is closely related to the
Ataxia Teleangiectasia gene product (ATM). TOR was first identified in S.
Cerevisiae where it controls cell growth and proliferation in response to
nutrient signals. When high quality N-and fermentable C-sources are available,
TOR promotes growth. When nutrients are limiting (or in the presence of
rapamycin) the fall in TOR activity inhibits overall mRNA translation (thereby
arresting growth), activates autophagy as well as proteosomal degradation of
specific proteins, and alters gene transcription by activation of the N- and C-
catabolite repression responses and by inhibition of ribosome biogenesis. These
responses are controlled by TOR kinase activity, which signals through two
primary effector limbs; through TOR-catalyzed phosphorylation, which alters
target function or marks targets for degradation, and through the modulation of
protein phosphatase activity, achieved by TOR-catalyzed phosphorylation of the
phosphatase regulatory protein Tap42.
In multicellular organisms, TOR control of cell growth is shared with the
IR/IGF1R tyrosine kinases. We and others have shown that mTOR controls the
function of a subset of the downstream targets of the Type 1A PI-3 kinases,
especially the p70 S6 kinase and the eIF-4E inhibitor proteins, PHASI/4E-BP.
Thus, rapamycin or withdrawal of amino acids produces dephosphorylation of p70
S6K and 4E-BP, which become unresponsive to insulin and P1-3 kinase.
Concomitantly, the translation of several subsets of rnRNA critical to growth
are inhibited. Although we showed that mTOR can phosphorylate and activate the
p70 S6 kinase in vitro, our data indicate that mTOR regulation of p70 S6K in
vivo occurs indirectly, through the regulation of phosphatase activity.
Moreover, the molecular basis for the regulation of mTOR activity by nutrients
and tyrosine kinases is unknown.
We propose to study the mechanism of mTOR regulation and signaling by a
combination of genetics and biochemistry. We have identified loss-of-function
mutants in C. elegans TOR; these arrest as undersized larvae. We are carrying
out a screen for suppressor mutants, seeking the elements downstream of CeTOR
most critical to its function in development. A second effort involves direct
biochemical experiments addressing the mechanism by which mTOR regulates
protein phosphatase activity. Finally, we will characterize in vitro the basis
for the radically different TOR kinase activity toward p70 S6K and 4E BP, and
seek to identify the molecular basis for mTOR regulation in vivo.
描述(由申请人提供):TOR被发现是最大的 雷帕霉素;后者是一种有效的和临床上重要的免疫抑制剂
和潜在的抗增殖药物。所有雷帕霉素的药理作用
这是因为它具有抑制TOR功能的能力。TOR是一种巨大的蛋白质
PIK家族中的一种激酶,其催化结构域与PIK家族中的
共济失调毛细血管扩张基因产物(ATM)。TOR首先在S.
其中它控制细胞的生长和增殖,以响应
营养信号当高质量的氮源和可发酵的碳源可用时,
TOR促进增长。当营养物质有限时(或在存在
雷帕霉素),TOR活性的下降抑制整体mRNA翻译(从而
抑制生长),激活自噬以及蛋白体降解,
特异性蛋白质,并通过激活N-和C-
分解代谢物阻遏反应和抑制核糖体生物合成。这些
反应由TOR激酶活性控制,其通过两个
初级效应肢;通过TOR催化的磷酸化,
目标功能或标记目标的退化,并通过调制
蛋白磷酸酶活性,通过TOR催化的磷酸化实现
磷酸酶调节蛋白Tap 42。
在多细胞生物体中,TOR对细胞生长的控制与细胞生长的控制共享。
IR/IGF 1 R酪氨酸激酶。我们和其他人已经证明,mTOR控制着
1A型PI-3激酶的下游靶的子集的功能,
特别是p70 S6激酶和eIF-4 E抑制蛋白PHASI/4 E-BP。
因此,雷帕霉素或氨基酸的去除产生p70的去磷酸化
S6 K和4 E-BP对胰岛素和P1-3激酶无反应。
与此同时,对生长至关重要的几种mRNA亚群的翻译
被抑制了。虽然我们发现mTOR可以磷酸化并激活
p70 S6激酶,我们的数据表明mTOR对p70 S6激酶的调节在体外是可能的。
体内通过调节磷酸酶活性间接发生。
此外,营养素调节mTOR活性的分子基础
和酪氨酸激酶是未知的。
我们建议研究mTOR的调节和信号转导机制,
遗传学和生物化学的结合。我们已经确定了功能丧失
突变体C. elegans TOR;这些逮捕作为小型幼虫。我们是带
筛选抑制突变体,寻找CeTOR下游的元件
对它在发展中的作用至关重要。第二项努力涉及直接
解决mTOR调节机制的生化实验
蛋白磷酸酶活性最后,我们将在体外表征的基础上,
对于对p70 S6 K和4 E BP的完全不同的TOR激酶活性,以及
寻求确定体内mTOR调节的分子基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH AVRUCH其他文献
JOSEPH AVRUCH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH AVRUCH', 18)}}的其他基金
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression
解码细胞生理学和肿瘤抑制中的 MST1 和 MST2 激酶
- 批准号:
8105217 - 财政年份:2010
- 资助金额:
$ 34.64万 - 项目类别:
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression
解码细胞生理学和肿瘤抑制中的 MST1 和 MST2 激酶
- 批准号:
7984806 - 财政年份:2010
- 资助金额:
$ 34.64万 - 项目类别:
The Boston Area Diabetes Endocrinology Research Center
波士顿地区糖尿病内分泌研究中心
- 批准号:
8063421 - 财政年份:2010
- 资助金额:
$ 34.64万 - 项目类别:
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression
解码细胞生理学和肿瘤抑制中的 MST1 和 MST2 激酶
- 批准号:
8244374 - 财政年份:2010
- 资助金额:
$ 34.64万 - 项目类别:
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression
解码细胞生理学和肿瘤抑制中的 MST1 和 MST2 激酶
- 批准号:
8450270 - 财政年份:2010
- 资助金额:
$ 34.64万 - 项目类别:














{{item.name}}会员




